A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics from pre-treatment to post-treatment imaging and the patients' outcomes.
The research provides valuable insights into the potential of TGR as a novel prognostic imaging biomarker in the context of CAR-T therapy for patients with relapsed or refractory non-Hodgkin's lymphoma.
Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients
Related Resources
Related Resources
Fostering Consistent Application and Interpretation of the Treatment Response Criteria Across Europe and Beyond
Last week Mint Medical supported an ESOI-EORTC joint hands-on course on imaging in assessing response to cancer therapy - a yearly event that took…
Structure, Gather, and Share Data Faster with the mint Lesion™ Browser-Based Application
Whether in clinical routine, in clinical trials or in clinical research, mint Lesion™ is a reliable and strong supporter of its users’ individual…